Impact of anti-human IgG hinge peptide antibodies on identification of patients with early seronegative rheumatoid arthritis
Authors' conclusion
Specific AHAs in combination with MMP-3 and CDAI are potentially useful to discriminate SNRA from non-RA.
Study context
- Population
- DMARD-naive patients with early seropositive RA (SPRA), seronegative rheumatoid arthritis (SNRA) and non-RA (disease duration < 2 years), and healthy controls
- Participants
- 43 / 21 / 49 / 58
- Comparison
- Anti-human IgG hinge antibodies (anti-hinge antibodies (AHAs)), alone and combined with MMP-3 and clinical disease activity index (CDAI), for discriminating SNRA from non-RA
- SPRAn = 43
- SNRAn = 21
- non-RAn = 49
- HCn = 58reference
- Outcome
- Discrimination of SNRA from non-RA (AUC from logistic regression and ROC analyses)
Methodological detailsELISA, logistic regression and ROC curve analyses
- ELISA
- Logistic regression and ROC curve analyses
Performance
As reported in the abstract
Discrimination of SNRA from non-RA (AUC)
MMP-3 + AHAs against IgG4 hinge peptide analogues, AUC
0.94
MMP-3 + AHAs against IgG1 hinge peptide analogues + CDAI, AUC
0.997
Further findings
IgG AHA levels across groups
- SPRA≥SNRA≈non-RA>HC
Original publication
Impact of anti-human IgG hinge peptide antibodies on identification of patients with early seronegative rheumatoid arthritis. Clin Exp Rheumatol. Published 7 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →